芪归坚骨方联合常规西药治疗肾虚血瘀型骨质疏松症临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R681

基金项目:


Clinical Study on Qigui Jiangu Prescription Combined with Routine Western Medicine for Osteoporosis of Kidney Deficiency and Blood Stasis Type
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察芪归坚骨方联合常规西药治疗肾虚血瘀型骨质疏松症的临床疗效及对骨钙代谢和腰椎骨密度的影响。方法:回顾性选取82 例肾虚血瘀型骨质疏松症患者,按治疗方法不同分为观察组40 例和对照组42 例。对照组采用常规西药治疗,观察组在对照组基础上给予芪归坚骨方治疗。比较2 组治疗前后骨代谢、腰椎骨密度、中医证候积分、视觉模拟评分法(VAS) 评分,评价临床疗效及不良反应发生情况。结果:观察组总有效率为82.50%,高于对照组61.90%,差异有统计学意义(P<0.05)。治疗后,2 组骨特异性碱性磷酸酶(BALP)、甲状旁腺素(PTH) 水平较治疗前降低,25 羟维生素D3[25-(OH)D3]水平较治疗前升高(P<0.05);且观察组BALP、PTH 水平低于对照组,25-(OH)D3 水平高于对照组(P<0.05)。治疗后,2 组腰椎骨密度高于治疗前,VAS 评分低于治疗前(P<0.05);且观察组腰椎骨密度高于对照组,VAS 评分低于对照组(P<0.05)。治疗后,2 组各项中医证候评分及总积分较治疗前降低,且观察组各项中医证候评分及总积分均低于对照组,差异均有统计学意义(P<0.05)。结论:芪归坚骨方联合常规西药治疗肾虚血瘀型骨质疏松症患者可调节骨代谢,有效改善临床症状及腰椎骨密度,缓解疼痛程度。

    Abstract:

    Abstract:Objective:To observe the clinical effect of Qigui Jiangu prescription combined with routine western medicine for osteoporosis of the kidney deficiency and blood stasis type and its effect on bone calcium metabolism and lumbar bone mineral density. Methods: A total of 82 cases of patients with osteoporosis of the kidney deficiency and blood stasis type selected retrospectively and assigned to the observation group and the control group according to different treatment methods,with 40 and 42 cases in each group respectively. The control group was treated with routine western medicine,and the observation group was treated with Qigui Jiangu prescription on the basis of the control group. Bone metabolism, lumbar bone mineral density,Chinese medicine syndrome scores and Visual Analogue Scale(VAS) scores were compared between the two groups before and after treatment;clinical effects and the incidence of adverse reactions were evaluated. Results:The total effective rate was 82.50% in the observation group, higher than that of 61.90% in the control group,the difference being significant(P<0.05). After treatment,the levels of bone alkaline phosphatase(BALP) and parathyroid hormone(PTH) in the two groups were decreased when compared with those before treatment,and the levels of 25- hydroxyvitamin D3[25- (OH) D3] were increased(P<0.05); the levels of BALP and PTH in the observation group were lower than those in the control group, and the level of 25- (OH)D3 was higher(P<0.05). After treatment, lumbar bone mineral density in the two groups was higher than that before treatment, and VAS scores were lower(P<0.05); lumbar bone mineral density in the observation group was higher than that in the control group,and VAS score was lower(P<0.05). After treatment,Chinese medicine syndrome scores and the total score in the two groups were decreased when compared with those before treatment(P<0.05); Chinese medicine syndrome scores and the total score in the observation group were lower than those in the control group, differences being significant(P<0.05). Conclusion: Qigui Jiangu prescription combined with routine western medicine for osteoporosis of the kidney deficiency and blood stasis type can regulate bone metabolism,effectively improve clinical symptoms and lumbar bone mineral density,and relieve pain.

    参考文献
    相似文献
    引证文献
引用本文

喻灿明,颜峰,丁志清.芪归坚骨方联合常规西药治疗肾虚血瘀型骨质疏松症临床研究[J].新中医,2022,54(19):133-137

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-10-08
  • 出版日期:
文章二维码